News Hub | News Direct

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

Protalix BioTherapeautics Inc.

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX–102), a drug candidate for the treatment of adult patients with Fabry disease. Fabry disease is a rare enzyme deficiency that afflicts 1 in 40,000 to 60,000 people worldwide. Patients with Fabry are unable to break down the fatty substance globotriaosylceramide (Gb3), leading to accumulation of Gb3 in the blood vessels and symptoms including impaired blood circulation, end-organ failure, and increased risk of heart attack and stroke. "The resubmission of the BLA represents a significant milestone for Protalix and we believe it has meaningful potential for patients and families affected by Fabry disease,” said Dror Bashan, Protalix's President and Chief Executive Officer. "Together with Chiesi, we are committed to continuing to work with the FDA toward our goal of achieving regulatory approval and making PRX–102 available to patients with this rare disease in the United States." A Step Closer To Important Treatment Protalix develops treatments from its proprietary plant cell-based expression system, ProCellEx ®. Its drug candidate PRX-102 is a modified recombinant α–Galactosidase–A enzyme that would allow the Fabry disease patient to digest Gb3. This drug is part of Protalix’s novel PEGylated enzyme replacement therapy (ERT) treatment. The resubmission of the BLA for drug candidate PRX-102 involves a rigorous and comprehensive set of data on the therapy. Protalix is confident moving forward, as it was the first company to receive Food and Drug Administration (FDA) approval of a protein produced through a plant cell-based expression system. Now it is collaborating with the rare disease unit of the Chiesi Group, an Italian-based therapeutic development company, to develop and commercialize PRX-102 for the treatment of Fabry disease. “We believe it is important to deliver a potential new treatment option," said Giacomo Chiesi, head of Chiesi Global Rare Diseases, commenting on the resubmission of the BLA. "Together with Protalix, we thank the investigators and study participants who have made reaching this milestone possible and have supported our joint commitment to bringing this new treatment option to the Fabry patient community." Protalix anticipates the FDA will review the resubmission within the next 6 months. Other companies looking to develop treatments for Fabry disease include Avrobio Inc. (NASDAQ: AVRO), Freeline Therapeutics Holdings PLC (NASDAQ: FRLN), and Sangamo Therapeutics Inc. (NASDAQ: SGMO). To learn more about Protalix BioTherapeutics, click here. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Chuck Padala, Managing Director- LifeSci Advisors +1 646-627-8390 chuck@lifesciadvisors.com Company Website https://protalix.com/

November 30, 2022 02:59 PM Eastern Standard Time

RKS WINS MAJOR RULING: FRAUDULENT TRANSFER CLAIMS AGAINST BAUSCH HEALTH, BAUSCH + LOMB WILL MOVE FORWARD

Rolnick Kramer Sadighi LLP (RKS)

In an important step in protecting their clients’ interests and preventing Bausch Health Companies (“Bausch Health”) from putting the assets of Bausch + Lomb (“B+L”) beyond the reach of judgment creditors through a corporate spin-off, Rolnick Kramer Sadighi LLP (“RKS”) has secured a vital legal ruling that will allow their clients to pursue fraudulent transfer claims against Bausch Health and B+L in New Jersey state court. United States District Judge Michael A. Shipp granted RKS’s motion to remand their clients’ fraudulent transfer action against Bausch Health and B+L back to state court, holding that Bausch Health and B+L had improperly removed the action to federal court earlier this year. In removing the action, the defendants purported to rely on a 1998 federal law (the Securities Litigation Uniform Standards Act or “SLUSA”), which was designed by Congress to prevent securities fraud strike suits from being filed in state court. Defendants argued that SLUSA barred Plaintiffs’ fraudulent transfer claims. Judge Shipp agreed with RKS that SLUSA does not apply to RKS’s clients’ declaratory judgment action brought pursuant to New Jersey’s fraudulent transfer statute because: (i) the relief RKS seeks on behalf of its clients is a declaration that the spin-off is voidable, such that they may continue to look to B+L’s assets to satisfy their claims against Bausch Health; and (ii) securities fraud is not a factual predicate of the fraudulent transfer claims. RKS’s clients’ fraudulent transfer action will now proceed against Bausch Health and B+L in state court. Following this adverse ruling by the Federal District Court, Bausch Health has designated Bausch + Lomb as an unrestricted subsidiary. About RKS: Rolnick Kramer Sadighi, LLP (RKS) provides strategic litigation solutions for the investment management community. Launched in 2020, RKS is a premier securities litigation boutique dedicated to serving the investment management industry, including hedge funds, mutual funds, private equity, credit, real estate, and structured finance firms. For more information, visit RKS online: https://www.rksllp.com/. Contact Details Arielle Goren +1 212-717-5863 agoren@kivvit.com Company Website https://www.rksllp.com/

November 30, 2022 10:45 AM Eastern Standard Time

Alberta Becomes the First Province to Regulate Psychoactives for Therapeutic Purposes

MarketJar

The modern psychoactive renaissance is continuing to gain momentum, with Alberta becoming the latest region to propose regulatory changes regarding the substances. On October 5, Government officials declared that Alberta will be the first province in Canada to regulate psychoactives for the treatment of psychiatric disorders. Although doctors and researchers are allowed to apply to Health Canada for permission to use psychoactives in clinical research or grant patients special access for therapeutic use, they are still illegal in Canada. According to Alberta's new laws, medical professionals must submit an application to the province for a license before administering psychoactives to patients with mental illnesses. Alberta's new laws governing the therapeutic use of psychoactives are expected to take effect on January 16, 2023. At a time when the mental health crisis is getting worse and more people are turning to alternative treatment providers for assistance, these regulatory changes are timely. According to John Hopkins Medicine, over 6.7 million people in Canada experience mental illnesses, compared to 26% of Americans age 18 and older who experience a diagnosable mental disorder each year. Psilocybin has recently attracted renewed interest as a potential treatment for conditions like anxiety, addiction, and depression. And these recent changes to the law demonstrate the legitimacy of psychoactive-assisted therapy within the health care system. Companies in the market stand to gain as psychoactives become more accepted, especially those that provide high-quality goods and integrated mental health care treatment options at clinics. The development and provision of cutting-edge mental health care and access to secure, scientifically supported psychoactive-assisted therapies are the main priorities of Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF), a leading provider of integrated mental healthcare. The range of mental health services Numinus offers and its network of wellness centers across Canada and the US have kept growing. One of the reasons behind Numinus ’ ongoing growth is its growth-focused strategy. Over the last couple of years, the company has made several sizable acquisitions that have directly contributed to its bottom line. In 2021, Numinus added Neurology Centre of Toronto and Mindspace to the company, both of which are responsible for the notable uptick in revenue in the past year. Then in June 2022, the company completed the acquisition of Novamind, along with its network of wellness clinics, bringing its total network to 12 wellness clinics, four research facilities and a dedicated psychoactives research lab. On November 29, Numinus announced its Q4 and full year results, revealing a 643% increase in fourth quarter revenue thanks to the acquisition of Novamind. The company reported C$4.2 million in revenue for Q4, $3.7 million of which came from its wellness clinic network. Numinus also grew its gross margin to 31.5% in the fourth quarter, generating $1.3 million in gross profit and ended the quarter with a $33 million cash position. “Fiscal 2022 was a pivotal year for Numinus, as we entered the US market with the transformational acquisition of Novamind, expanded our Ketamine-assisted Therapy offering across Canada, launched a formal practitioner training program, and unveiled a global rebranding of our company. Combined, these efforts have provided a solid platform for our continued, measured growth – with scalable infrastructure and systems, and a growing pipeline of practitioners choosing Numinus for their psychedelics-assisted therapy training,” said Payton Nyquvest, Founder and CEO of Numinus. “With our strong wellness clinic network and a growing clinical research division, Numinus is one of the best positioned companies in the sector – supported by diversified revenue streams, growing brand awareness, and a recognized pathway to profitability.” Commenting on the quarter, Nyquvest continued: “Our fiscal fourth quarter was the first to demonstrate the real power of our larger, cross-border platform following the acquisition of Novamind on June 10, 2022 – and the impacts are evident in our performance. Compared to the previous quarter, fourth quarter revenues grew 464% to $4.2 million, gross margin improved by 710 basis points from 6.5% to 31.5%, and gross profit grew 628% to $1.3 million. We’re excited about the momentum building across our business and the regulatory reform underway across the US and Canada, and will continue to evaluate complementary growth opportunities that will enhance our client experience and further support margin expansion.” During Q4 2022, Numinus completed over 17,000 client appointments, which represents a 202% increase in clinic appointments compared to over 5,600 appointments in Q3 2022, mostly due to the acquisition of Novamind at the beginning of the quarter. Numinus acquired Novamind in June 2022, along with its network of wellness clinics. This brings its total network to 13 wellness clinics, four research facilities and a dedicated psychoactives research lab. And this is just the beginning of what this company plans to achieve. To learn more about Numinus Wellness (TSX:NUMI) (OTCQX:NUMIF) and how it is pioneering the integration of psychoactive-assisted therapies into standard clinical practice, click this link or visit the company’s website Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Numinus Wellness Inc. Market Jar Media Inc. has or expects to receive from Numinus Wellness Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) one hundred nine thousand four hundred and forty USD for 23 days (16 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Numinus Wellness Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Numinus Wellness Inc.’s industry; (b) market opportunity; (c) Numinus Wellness Inc.’s business plans and strategies; (d) services that Numinus Wellness Inc. intends to offer; (e) Numinus Wellness Inc.’s milestone projections and targets; (f) Numinus Wellness Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Numinus Wellness Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Numinus Wellness Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Numinus Wellness Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Numinus Wellness Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Numinus Wellness Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Numinus Wellness Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Numinus Wellness Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Numinus Wellness Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Numinus Wellness Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Numinus Wellness Inc.’s business operations (e) Numinus Wellness Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Numinus Wellness Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Numinus Wellness Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Numinus Wellness Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Numinus Wellness Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Numinus Wellness Inc. or such entities and are not necessarily indicative of future performance of Numinus Wellness Inc. or such entities.. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

November 30, 2022 07:30 AM Pacific Standard Time

Image

New York Issues First 36 Licences for Recreational Cannabis Dispensaries

MarketJar

Over the past ten years, the legal cannabis market in North America has advanced significantly. Another 20 states have joined the movement since Colorado made history by legalizing recreational marijuana in 2012, and several more may soon do the same. On November 21, New York took a monumental step in establishing a legal and lucrative marketplace for recreational marijuana by issuing its first 36 dispensary licenses. The majority of the businesses are owned by people who have been disproportionately impacted by the drug war, while others are run by nonprofit organizations. The licenses approved by the state's Cannabis Control Board were the first of 175 that the state intends to issue, with many of the first round reserved for applicants with prior cannabis-related convictions. Even though the licensing program was being challenged in court, the state Cannabis Control Board voted to give licenses to 28 entrepreneurs and eight nonprofits. This will complete a supply chain from seed to sale, which should allow legal sales to start in the state. The goal of the licensing process was to help the state reach its goal of giving people from underserved areas priority for jobs in the legal cannabis industry. Even though people of all races used marijuana at about the same rate, marijuana prohibition in New York and the rest of the country mostly brought Black and Latino people into the criminal justice system. In March of 2018, New York made it legal for adults to use cannabis for fun. This meant that each person could have up to three ounces of weed or 24 grams of concentrate. Officials say that sales will start in stores before the end of 2022. In the first round, businesses and organizations competed for 175 licenses, which let operators open up to three dispensaries. Most of them, about 150, are expected to go to businesses that the state will help open by renting them turnkey spaces and giving them loans to cover the cost of getting their storefronts ready. The last 25 licenses are set aside for organizations that help people in need. The number of cannabis products available on the market is growing as more states legalize marijuana for recreational purposes. The three-pillar business plan of Flora Growth Corp. (NASDAQ:FLGC), a next-generation cannabis firm with a focus on commercial wholesale, consumer brands, and life sciences, makes it unique in the market. For the diverse applications of cannabis and other plant-based products, Flora Growth creates a wide variety of brands and services. The business has operations in multiple countries and diversified revenue streams. Flora Growth Reports Another Record Quarter Flora Growth has continued to achieve positive revenue growth in 2022. On November 28, the company reported Q3 2022 revenue of US$10.8 million, a 414% increase from the previous year and $25.7 million in revenue for the first nine months of 2022, which represents an increase of 510% year-over-year (YoY). The revenue increase is primarily attributed to acquired brands, JustCBD and Vessel. Flora Growth also increased its gross profit by approximately 703% YoY to approximately $5.0 million. “The third quarter of 2022 was another exciting quarter for Flora as we continued to lay the foundation of our business for the long-term, ” said Flora Growth Chairman and CEO Luis Merchan. “During the quarter, we exported products to several new markets, including distribution of our Colombian grown dried flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States. Our global distribution network, coupled with our high-quality Colombian flower and derivatives, leave Flora well positioned to capitalize on the evolving global cannabis landscape.” Additionally, Flora Growth reaffirmed that it is on track to generate $35 to 45 million in revenue in 2022. To learn more about Flora Growth Corp (NASDAQ:FLGC), please click this link or visit the company’s website. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Flora Growth Corp. Market Jar Media Inc. has or expects to receive from Flora Growth Corp’s Digital Marketing Agency of Record (Native Ads Inc.) nineteen thousand USD for 7 days (5 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Flora Growth Corp.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Flora Growth Corp.’s industry; (b) market opportunity; (c) Flora Growth Corp.’s business plans and strategies; (d) services that Flora Growth Corp. intends to offer; (e) Flora Growth Corp.’s milestone projections and targets; (f) Flora Growth Corp.’s expectations regarding receipt of approval for regulatory applications; (g) Flora Growth Corp.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Flora Growth Corp.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Flora Growth Corp.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Flora Growth Corp.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Flora Growth Corp.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Flora Growth Corp.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Flora Growth Corp. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Flora Growth Corp.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Flora Growth Corp.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Flora Growth Corp.’s business operations (e) Flora Growth Corp. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Flora Growth Corp. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Flora Growth Corp. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Flora Growth Corp. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Flora Growth Corp. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Flora Growth Corp. or such entities and are not necessarily indicative of future performance of Flora Growth Corp. or such entities. Contact Details Market Jar Media Inc. James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

November 30, 2022 06:30 AM Pacific Standard Time

Image

CORRECTION: Expansion of Pipeline to Mental Health

The Chicago School of Professional Psychology

Nearly half of U.S. psychologists in a new survey say they cannot meet the growing demand for services and three-quarters say they have longer waiting lists than before the pandemic. “This new survey confirms what we have already heard from patients: people are having a hard time accessing the mental health services they need,” said Dr. Michele Nealon, Psy.D., President of The Chicago School of Professional Psychology. “It is critical now more than ever to expand the pipeline for mental health professionals and promote integrated behavioral health into primary care.” The 2022 COVID-19 Practitioner Impact Survey of almost 2,300 psychologists by the American Psychological Association found that demand for treatment of anxiety and depression remained high for the third consecutive year, along with increased demand for treatment of stressor-related disorders, and substance use disorders. Six in 10 practitioners said they had no more openings for new patients, nearly half (46%) said they had been unable to meet treatment demand and nearly three quarters (72%) have longer waiting lists than before the pandemic. On average, psychologists reported being contacted by more than 15 potential new patients seeking care per month. Nearly eight in 10 psychologists (79%) said they had seen an increase in the number of patients with anxiety disorders since the start of the pandemic, and 66% had seen an increase in the demand for treatment for depression. Almost half (47%) said they had seen an increase in demand for substance use treatment (compared to 43% last year) and 64% had seen an increase in demand for trauma treatment (compared to 62% last year). 2021). Additionally, two-thirds of psychologists reported seeing an increase in symptom severity among patients in 2022. “The social, emotional, and economic effects of a pandemic are still with us and will be for quite some time. In addition, the stressors associated with inflation, social and racial inequities, political upheaval, and international tensions are creating an unsettled nation. At a time when mental health services are needed the most, we are struggling the most to meet those needs,” said Dr. Nealon. “Policy makers have to make a bigger investment in financial and programmatic support to ensure that everyone who seeks psychological services can find a professional who can understand and help them.” The Chicago School of Professional Psychology is a non-profit majority minority institution, educating 6,000 students at seven campuses in major metro areas around the national. Two of three identify as students of color, including a significant number of first-generation college students. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

November 29, 2022 06:18 PM Eastern Standard Time

Induction Healthcare Group focused on "building out core capability"

Induction Healthcare Group PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 29, 2022 07:00 AM Eastern Standard Time

Video

Expansion of Pipeline to Mental Health

The Chicago School of Professional Psychology

Nearly half of U.S. psychologists in a new survey say they cannot meet the growing demand for services and three-quarters say they have longer waiting lists than before the pandemic. “This new survey confirms what we have already heard from patients: people are having a hard time accessing the mental health services they need,” said Dr. Michele Nealon, Psy.D., President of The Chicago School of Professional Psychology. “It is critical now more than ever to expand the pipeline for mental health professionals and promote integrated behavioral health into primary care.” The 2022 COVID-19 Practitioner Impact Survey of 2,300 psychologists by the American Psychological Association found that demand for treatment of anxiety and depression remained high for the third consecutive year, along with increased demand for treatment of trauma-related disorders, increased stressors, and substance use disorders. Six in 10 practitioners said they had no more openings for new patients, nearly half (46%) said they had been unable to meet treatment demand and nearly three quarters (72%) have longer waiting lists than before the pandemic. On average, psychologists reported being contacted by more than 15 potential new patients seeking care per week. Nearly eight in 10 psychologists (79%) said they had seen an increase in the number of patients with anxiety disorders since the start of the pandemic, and 66% had seen an increase in the demand for treatment for depression. Almost half (47%) said they had seen an increase in demand for addiction treatment (compared to 43% last year) and 64% had seen an increase in demand for trauma treatment (compared to 62% last year). 2021). Additionally, two-thirds of psychologists reported seeing an increase in symptom severity among patients in 2022. “The social, emotional, and economic effects of a pandemic are still with us and will be for quite some time. In addition, the stressors associated with inflation, social and racial inequities, political upheaval, and international tensions are creating an unsettled nation. At a time when mental health services are needed the most, we are struggling the most to meet those needs,” said Dr. Nealon. “Policy makers have to make a bigger investment in financial and programmatic support to ensure that everyone who seeks psychological services can find a professional who can understand and help them.” About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Kelton Gibson +1 661-607-2012 kgibson1@thechicagoschool.edu

November 28, 2022 10:55 AM Pacific Standard Time

The “Cannabis Science Fair” to Showcase Cannabis Research & Innovation

MCR Labs

Local cannabis testing leader MCR Labs is partnering with the Cannabis Center of Excellence (CCoE) to host the “Cannabis Science Fair.” The event returns for its second year to show off the important work major academic and commercial institutions are conducting to further our knowledge of cannabis. The fair, which is free and open to the public, will feature poster presentations and speakers from academic institutions like Harvard and companies like Biomerieux and Smokenol. “After such a great response last year, we are stoked to present new, exciting research and innovation at this year’s fair,” said Melissa Kenton, MCR Lab’s Events & Outreach Manager and the main organizer behind the event. “There is a huge demand and curiosity for more information on cannabis, and we are happy to provide a venue for professionals in the field to share their knowledge.” MCR Labs provides product compliance testing to licensed cannabis producers, but advancing research efforts is also an important part of the company’s mission. Several of the company’s scientists will be there showcasing the research they’ve conducted on topics ranging from the effects of growing environment on cannabis to the relationship between phosphorus and arsenic in the plant. Dr. Staci Gruber, Director of Marijuana Investigations for Neuroscientific Discovery (MIND) Program at McLean Hospital, will be giving the first keynote presentation of the day titled “What to Keep in MIND: Recreational vs. Medical Cannabis.” Jeff Rawson, a Harvard Postdoctoral Fellow, will give the second talk of the day titled “Is Misinformation Common in Cannabis Markets?” “The Cannabis Science Fair” will be held at the Harvard University Science Center on Saturday, Dec. 3 from 11a.m to 5 p.m. Anyone interested in learning more or attending the event can find details on the event website. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

November 28, 2022 10:49 AM Eastern Standard Time

Image

C4X Discovery signs potential $402mln deal

C4X Discovery Holdings PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 28, 2022 09:30 AM Eastern Standard Time

Video